Episode: FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome
Description: Dr DiNardo discusses the the FDA approval of ivosidenib for patients with relapsed/refractory IDH1-mutant myelodysplastic syndromes, the unique mechanism of action of ivosidenib, and key efficacy and safety findings from the AG120-C-001 trial.
Click any word to see translations, usage examples & similar words. Then learn them using saved words.
Text not synced with the audio? See here for why certain podcasts won't sync.
